-
1
-
-
0032507027
-
Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
-
HOGG RS, HEATH KV, YIP B et al.: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. J. Am. Med. Assoc. (1998) 279(6):450-454.
-
(1998)
J. Am. Med. Assoc.
, vol.279
, Issue.6
, pp. 450-454
-
-
Hogg, R.S.1
Heath, K.V.2
Yip, B.3
-
2
-
-
2642709177
-
Declining morbidity and mortality among patients with advanced human immunodeficiency virus
-
infection HIV Outpatient Study Investigators
-
PALELLA FJ Jr, DELANEY KM, MOORMAN AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. (1998) 338(13):853-860.
-
(1998)
N. Engl. J. Med.
, vol.338
, Issue.13
, pp. 853-860
-
-
Palella Jr., F.J.1
Delaney, K.M.2
Moorman, A.C.3
-
3
-
-
3042726798
-
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA Panel
-
YENI PG, HAMMER SM, HIRSCH MS et al.: Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA Panel. J. Am. Med. Assoc. (2004) 292(2):251-265.
-
(2004)
J. Am. Med. Assoc.
, vol.292
, Issue.2
, pp. 251-265
-
-
Yeni, P.G.1
Hammer, S.M.2
Hirsch, M.S.3
-
4
-
-
0033576816
-
Efavirenz plus zidovudine lamivudine efavirenz plus indinavir indinavir plus zidovudine lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team
-
STASZEWSKI S, MORALES-RAMIREZ J, TASHIMA KT et al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N. Engl. J. Med. (1999) 341(25):1865-1873.
-
(1999)
N. Engl. J. Med.
, vol.341
, Issue.25
, pp. 1865-1873
-
-
Staszewski, S.1
Morales-ramirez, J.2
Tashima, K.T.3
-
5
-
-
0034604276
-
Adherence to protease inhibitor therapy outcomes in patients with HIV infection
-
PATERSON DL, SWINDELLS S, MOHR J et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. (2000) 133(1):21-30.
-
(2000)
Ann. Intern. Med.
, vol.133
, Issue.1
, pp. 21-30
-
-
Paterson, D.L.1
Swindells, S.2
Mohr, J.3
-
6
-
-
17744418262
-
Predictors of virological success ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA study
-
PAREDES R, MOCROFT A, KIRK O et al.: Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch. Intern. Med. (2000) 160(8):1123-1132.
-
(2000)
Arch. Intern. Med.
, vol.160
, Issue.8
, pp. 1123-1132
-
-
Paredes, R.1
Mocroft, A.2
Kirk, O.3
-
7
-
-
0033550965
-
Clinical progression virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study
-
LEDERGERBER B, EGGER M, OPRAVIL M et al.: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet (1999) 353(9156):863-868.
-
(1999)
Lancet
, vol.353
, Issue.9156
, pp. 863-868
-
-
Ledergerber, B.1
Egger, M.2
Opravil, M.3
-
8
-
-
9444228307
-
Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: Results from the EuroSIDA study group
-
MOCROFT A, LEDERGERBER B, VIARD JP et al.: Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J. Infect. Dis. (2004) 190(11):1947-1956.
-
(2004)
J. Infect. Dis.
, vol.190
, Issue.11
, pp. 1947-1956
-
-
Mocroft, A.1
Ledergerber, B.2
Viard, J.P.3
-
9
-
-
20144386998
-
Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: Multicentre cohort study
-
SABIN CA, HILL T, LAMPE F et al.: Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. Br. Med. J. (2005) 330(7493):695.
-
(2005)
Br. Med. J.
, vol.330
, Issue.7493
, pp. 695
-
-
Sabin, C.A.1
Hill, T.2
Lampe, F.3
-
10
-
-
10044230450
-
Strategies for overcoming resistance in HIV- 1 infected patients receiving HAART
-
CLOTET B: Strategies for overcoming resistance in HIV- 1 infected patients receiving HAART. AIDS Rev. (2004) 6(3):123-130.
-
(2004)
AIDS Rev.
, vol.6
, Issue.3
, pp. 123-130
-
-
Clotet, B.1
-
11
-
-
0035808534
-
Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens
-
MONTANER JSG, HARRIGAN PR, JAHNKE N et al.: Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS (2001) 15(1):61-69.
-
(2001)
AIDS
, vol.15
, Issue.1
, pp. 61-69
-
-
Montaner, J.S.G.1
Harrigan, P.R.2
Jahnke, N.3
-
12
-
-
0037055027
-
Dual versus single protease inhibitor therapy following antiretroviral treatment failure
-
HAMMER SM, VAIDA F, BENNETT KK et al.: Dual versus single protease inhibitor therapy following antiretroviral treatment failure. J. Am. Med. Assoc. (2002) 288(2):169-180.
-
(2002)
J. Am. Med. Assoc.
, vol.288
, Issue.2
, pp. 169-180
-
-
Hammer, S.M.1
Vaida, F.2
Bennett, K.K.3
-
13
-
-
0033047131
-
Structure-based discovery of tipranavir disodium (PNU-140690E): A potent orally bioavailable nonpeptidic HIV protease inhibitor
-
THAISRIVONGS S, STROHBACH JW: Structure-based discovery of tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Biopolymers (1999) 51(1):51-58.
-
(1999)
Biopolymers
, vol.51
, Issue.1
, pp. 51-58
-
-
Thaisrivongs, S.1
Strohbach, J.W.2
-
14
-
-
12944322516
-
Tipranavir (PNU-140690): A potent orally bioavailable nonpeptidic HIV protease inhibitor of the 56-dihydro-4-hydroxy-2-pyrone sulfonamide class
-
TURNER SR, STROHBACH JW, TOMMASI RA et al.: Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med. Chem. (1998) 41(18):3467-3476.
-
(1998)
J. Med. Chem.
, vol.41
, Issue.18
, pp. 3467-3476
-
-
Turner, S.R.1
Strohbach, J.W.2
Tommasi, R.A.3
-
15
-
-
13844296701
-
Pharmacokinetic characterization of different dose combinations of coadministered tipranavir ritonavir in healthy volunteers
-
MacGREGOR TR, SABO JP, NORRIS SH et al.: Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin. Trials (2004) 5(6):371-382.
-
(2004)
HIV Clin. Trials
, vol.5
, Issue.6
, pp. 371-382
-
-
MacGregor, T.R.1
Sabo, J.P.2
Norris, S.H.3
-
16
-
-
1542409142
-
A 14-day dose-response study of the efficacy safety pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients
-
McCALLISTER S, VALDEZ H, CURRY K et al.: A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. (2004) 35(4):376-382.
-
(2004)
J. Acquir. Immune Defic. Syndr.
, vol.35
, Issue.4
, pp. 376-382
-
-
McCallister, S.1
Valdez, H.2
Curry, K.3
-
17
-
-
29844451824
-
Evaluation of the bioavailability of tipranavir/ritonavir (TPV/r) 500mg/200mg oral solution (OS): Comparison to TPV capsules the influence of food intake in healthy volunteers
-
Quebec Canada (April 28 - 30) (Abstract 42)
-
SABO JP, HUETTNER S, MacGREGOR T: Evaluation of the bioavailability of tipranavir/ritonavir (TPV/r) 500mg/200mg oral solution (OS): comparison to TPV capsules, and the influence of food intake in healthy volunteers. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, Canada (April 28 - 30 2005) (Abstract 42).
-
(2005)
6th International Workshop on Clinical Pharmacology of HIV Therapy
-
-
Sabo, J.P.1
Huettner, S.2
MacGregor, T.3
-
18
-
-
0012877758
-
Correlation of viral load reduction plasma levels in multiple protease inhibitor experienced patients taking tipranavir/ritonavir in a Phase IIB trial: BI 1182.52
-
Boston USA (Abstract 528)
-
YENI P MacGREGOR T, GATHE J et al.: Correlation of viral load reduction and plasma levels in multiple protease inhibitor experienced patients taking tipranavir/ritonavir in a Phase IIB trial: BI 1182.52. 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2003) (Abstract 528).
-
(2003)
10th Conference on Retroviruses Opportunistic Infections
-
-
Yeni, P.1
MacGregor, T.2
Gathe, J.3
-
19
-
-
29844434313
-
Population pharmacokinetic assessment of systemic steady-state tipranavir concentrations for adults administered tipranavir/ritonavir 500/200 mg twice daily
-
Boston USA (February 22 - 25) (Abstract 654)
-
YONG CL, SABO JP, OKSALA C et al.: Population pharmacokinetic assessment of systemic steady-state tipranavir concentrations for adults administered tipranavir/ritonavir 500/200 mg twice daily. 12th Conference on Retroviruses and Opportunistic Infections, Boston, USA (February 22 - 25 2005) (Abstract 654).
-
(2005)
12th Conference on Retroviruses Opportunistic Infections
-
-
Yong, C.L.1
Sabo, J.P.2
Oksala, C.3
-
20
-
-
29844451441
-
The pharmacokinetics of nucleoside reverse transcriptase inhibitors when coadministered with the HIV protease inhibitor tipranavir in HIV-1 infected patients
-
San Francisco USA (Abstract 81)
-
PHILLIPS L, BORIN M, HOPKINS NK, DAENZER CL, WANG Y: The pharmacokinetics of nucleoside reverse transcriptase inhibitors when coadministered with the HIV protease inhibitor tipranavir in HIV-1 infected patients. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA (2000) (Abstract 81).
-
(2000)
7th Conference on Retroviruses Opportunistic Infections
-
-
Phillips, L.1
Borin, M.2
Hopkins, N.K.3
Daenzer, C.L.4
Wang, Y.5
-
21
-
-
11244292470
-
Pharmacokinetics safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV) amprenavir (APV) or lopinavir (LPV): Interim analysis of BI 1182.51
-
Rome Italy (April 1 - 3) (Session 5)
-
LEITH J, WALMSLEY S, KATLAMA C et al.: Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV), amprenavir (APV), or lopinavir (LPV): interim analysis of BI 1182.51. 5th International Workshop on Clinical Pharmacology of HIV Therapy, Rome, Italy (April 1 - 3 2004) (Session 5).
-
(2004)
5th International Workshop on Clinical Pharmacology of HIV Therapy
-
-
Leith, J.1
Walmsley, S.2
Katlama, C.3
-
22
-
-
3543083046
-
The effect of tipranavir/ritonavir 500mg/200mg bid (TPV/r) on the pharmacokinetics of fluconazole in healthy volunteers
-
Rome Italy (April 1 - 3) (Abstract 4.8)
-
VAN HEESWIJK R, SABO JP, MacGREGOR T et al.: The effect of tipranavir/ritonavir 500mg/200mg bid (TPV/r) on the pharmacokinetics of fluconazole in healthy volunteers. 5th International Workshop on Clinical Pharmacology in HIV Therapy, Rome, Italy (April 1 - 3 2004) (Abstract 4.8).
-
(2004)
5th International Workshop on Clinical Pharmacology in HIV Therapy
-
-
Van Heeswijk, R.1
Sabo, J.P.2
MacGregor, T.3
-
23
-
-
3543149806
-
The pharmacokinetic interactions between tipranavir/ritonavir 500 mg/200 mg bid (TPV/r) atorvastatin antacid CYP3A4 in healthy volunteers
-
Rome Italy (April 1 - 3) (Abstract 5.2)
-
VAN HEESWIJK R, SABO JP COOPER C et al.: The pharmacokinetic interactions between tipranavir/ritonavir 500 mg/200 mg bid (TPV/r) and atorvastatin, antacid and CYP3A4 in healthy volunteers. 5th International Workshop on Clinical Pharmacology in HIV Therapy, Rome, Italy (April 1 - 3 2004) (Abstract 5.2).
-
(2004)
5th International Workshop on Clinical Pharmacology in HIV Therapy
-
-
Van Heeswijk, R.1
Sabo, J.P.2
Cooper, C.3
-
24
-
-
29844457606
-
The pharmacokinetics (PK) of single-dose steady-state tipranavir/ritonavir (TPV/r) 500mg/200mg in subjects with mild or moderate hepatic impairment
-
Quebec Canada (April 28 - 30) (Abstract 3.11)
-
COOPER C, VAN HEESWIJK R, BILODEAU M et al.: The pharmacokinetics (PK) of single-dose and steady-state tipranavir/ritonavir (TPV/r) 500mg/200mg in subjects with mild or moderate hepatic impairment. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, Canada (April 28 - 30 2005) (Abstract 3.11).
-
(2005)
6th International Workshop on Clinical Pharmacology of HIV Therapy
-
-
Cooper, C.1
Van Heeswijk, R.2
Bilodeau, M.3
-
25
-
-
0033956430
-
In vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors
-
BACK NK, VAN WIJK A, REMMERSWAAL D et al.: In vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. AIDS (2000) 14(1):101-102.
-
(2000)
AIDS
, vol.14
, Issue.1
, pp. 101-102
-
-
Back, N.K.1
Van Wijk, A.2
Remmerswaal, D.3
-
26
-
-
1642363348
-
Analysis of protease inhibitor combinations in vitro: Activity of lopinavir amprenavir tipranavir against HIV type 1 wild-type drug-resistant isolates
-
BULGHERONI E, CITTERIO P, CROCE F et al.: Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates. J. Antimicrob. Chemother. (2004) 53(3):464-468.
-
(2004)
J. Antimicrob. Chemother.
, vol.53
, Issue.3
, pp. 464-468
-
-
Bulgheroni, E.1
Citterio, P.2
Croce, F.3
-
27
-
-
0030671536
-
In vitro combination of PNU- 140690 a human immunodeficiency virus type 1 protease inhibitor with ritonavir against ritonavir-sensitive -resistant clinical isolates
-
CHONG KT, PAGANO PJ: In vitro combination of PNU- 140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob. Agents Chemother. (1997) 41(11):2367-2373.
-
(1997)
Antimicrob. Agents Chemother.
, vol.41
, Issue.11
, pp. 2367-2373
-
-
Chong, K.T.1
Pagano, P.J.2
-
28
-
-
0034623020
-
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples
-
LARDER BA, HERTOGS K, BLOOR S et al.: Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS (2000) 14(13):1943-1948.
-
(2000)
AIDS
, vol.14
, Issue.13
, pp. 1943-1948
-
-
Larder, B.A.1
Hertogs, K.2
Bloor, S.3
-
29
-
-
0035984802
-
In vitro antiviral interaction of lopinavir with other protease inhibitors
-
MOLLA A, MO H, VASAVANONDA S et al.: In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrob. Agents Chemother. (2002) 46(7):2249-2253.
-
(2002)
Antimicrob. Agents Chemother.
, vol.46
, Issue.7
, pp. 2249-2253
-
-
Molla, A.1
Mo, H.2
Vasavanonda, S.3
-
30
-
-
0030895692
-
Antiviral activity of the dihydropyrone PNU-140690 a new nonpeptidic human immunodeficiency virus protease inhibitor
-
POPPE SM, SLADE DE, CHONG KT et al.: Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. (1997) 41(5):1058-1063.
-
(1997)
Antimicrob. Agents Chemother.
, vol.41
, Issue.5
, pp. 1058-1063
-
-
Poppe, S.M.1
Slade, D.E.2
Chong, K.T.3
-
31
-
-
0034053044
-
Susceptibility to PNU- 140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors
-
RUSCONI S, LA SETA CATAMANCIO S, CITTERIO P et al.: Susceptibility to PNU- 140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob. Agents Chemother. (2000) 44(5):1328-1332.
-
(2000)
Antimicrob. Agents Chemother.
, vol.44
, Issue.5
, pp. 1328-1332
-
-
Rusconi, S.1
La Seta Catamancio, S.2
Citterio, P.3
-
32
-
-
0042450392
-
Tipranavir/ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients: BI 1182.52
-
Boston USA (Abstract 179)
-
GATHE J, KOHLBRENNER VM, PIERONE G et al.: Tipranavir/ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients: BI 1182.52. 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2003) (Abstract 179).
-
(2003)
10th Conference on Retroviruses Opportunistic Infections
-
-
Gathe, J.1
Kohlbrenner, V.M.2
Pierone, G.3
-
33
-
-
20844442867
-
OTHERS: RESIST-1: A Phase III, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in an antiretroviral (ARV)-experienced patients: 24 week data
-
Washington, DC, USA (October 30 - November 2) (Abstract H- 1137a)
-
HICKS C, OTHERS: RESIST-1: a Phase III, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in an antiretroviral (ARV)-experienced patients: 24 week data. 44th Interscience Conference on Antimicrobial Agents of Chemotherapy (ICAAC), Washington, DC, USA (October 30 - November 2 2004) (Abstract H- 1137a).
-
(2004)
44th Interscience Conference on Antimicrobial Agents of Chemotherapy (ICAAC)
-
-
Hicks, C.1
-
34
-
-
21944436966
-
TEAM R-S: 24 week data from RESIST-2: Phase III study of the efficacy and safety of background therapy plus tipranavir/ritonavir (TPV/r) or optimized ritonavir-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomized multicenter trial in treatment-experienced HIV + patients
-
Glasgow, UK (November 14 - 18) (Abstract PL-14.3)
-
CAHN P, TEAM R-S: 24 week data from RESIST-2: Phase III study of the efficacy and safety of background therapy plus tipranavir/ritonavir (TPV/r) or optimized ritonavir-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomized multicenter trial in treatment-experienced HIV + patients. 7th International Congress on Drug Therapy in HIV Infection, Glasgow, UK (November 14 - 18 2004) (Abstract PL-14.3).
-
(2004)
7th International Congress on Drug Therapy in HIV Infection
-
-
Cahn, P.1
-
35
-
-
20544455821
-
24-week RESIST study analyses: The efficacy of tipranavir/ritonavir is superior to lopinavir/ritonavir the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen
-
Boston USA (February 22 - 25) (Abstract 560)
-
COOPER D, HICKS C, CAHN P et al.: 24-week RESIST study analyses: the efficacy of tipranavir/ritonavir is superior to lopinavir/ritonavir, and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen. 12th Conference of Retroviruses and Opportunistic Infections, Boston, USA, (February 22 - 25 2005) (Abstract 560).
-
(2005)
12th Conference of Retroviruses Opportunistic Infections
-
-
Cooper, D.1
Hicks, C.2
Cahn, P.3
-
36
-
-
29844435158
-
Health-related quality of life with tipranavir in combination with an optimized background regimen in 2 randomized clinical trials
-
Boston USA (February 22 - 25) (Abstract 617)
-
WU A, HUANG IC, LOBO F, BERZON R: Health-related quality of life with tipranavir in combination with an optimized background regimen in 2 randomized clinical trials. 12th Conference on Retroviruses and Opportunistic Infections, Boston, USA (February 22 - 25 2005) (Abstract 617).
-
(2005)
12th Conference on Retroviruses Opportunistic Infections
-
-
Wu, A.1
Huang, I.C.2
Lobo, F.3
Berzon, R.4
-
37
-
-
0041949773
-
Baseline phenotypic susceptibility to tipranavir/ritonavir is retained in isolates from patients with multiple protease inhibitor experience (BI 1182.52)
-
Boston USA (Abstract 596)
-
COOPER D, HALL D, JAYAWEERA D et al.: Baseline phenotypic susceptibility to tipranavir/ritonavir is retained in isolates from patients with multiple protease inhibitor experience (BI 1182.52). 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA (2003) (Abstract 596).
-
(2003)
10th Conference on Retroviruses Opportunistic Infections
-
-
Cooper, D.1
Hall, D.2
Jayaweera, D.3
-
38
-
-
0038746305
-
Resistance to tipranavir is uncommon in a randomized trial of tipranavir/ritonavir (TPV/RTV) in multiple PI-failure patients (BI 1182.2)
-
Seattle USA (Abstract 562-T)
-
SCHWARTZ R, KAZANJIAN P, SLATER L et al.: Resistance to tipranavir is uncommon in a randomized trial of tipranavir/ritonavir (TPV/RTV) in multiple PI-failure patients (BI 1182.2). 9th Conference on Retroviruses and Opportunistic Infections, Seattle, USA (2002) (Abstract 562-T).
-
(2002)
9th Conference on Retroviruses Opportunistic Infections
-
-
Schwartz, R.1
Kazanjian, P.2
Slater, L.3
-
39
-
-
21944441495
-
Expected tipranavir resistance in a group of 589 patients with previous exposure to protease inhibitors
-
Rome Italy (March 11 - 13) (Session 3)
-
MIRANDA AC, DUQUE LM, CARVALHO AP et al.: Expected tipranavir resistance in a group of 589 patients with previous exposure to protease inhibitors. 2nd European HIV Drug Resistance Workshop, Rome, Italy (March 11 - 13 2004) (Session 3).
-
(2004)
2nd European HIV Drug Resistance Workshop
-
-
Miranda, A.C.1
Duque, L.M.2
Carvalho, A.P.3
-
40
-
-
14344256850
-
Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitors-experienced patients: Implications for tipranavir use
-
GALLEGO O, DE MENDOZA C, CORRAL A, BARRIOS A, SORIANO V: Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitors-experienced patients: implications for tipranavir use. AIDS Patient Care STDS (2005) 19(2):67-69.
-
(2005)
AIDS Patient Care STDS
, vol.19
, Issue.2
, pp. 67-69
-
-
Gallego, O.1
De Mendoza, C.2
Corral, A.3
Barrios, A.4
Soriano, V.5
-
41
-
-
20844435865
-
Effect of baseline genotype on response to tipranavir/ritonavir (TPV/r) compared with standard-of-care comparator (CPI/r) in treatment-experienced patients: The Phase III RESIST-1 -2 trials
-
Boston USA (February 22 - 25) (Abstract 104)
-
SCHAPIRO JM, CAHN P TROTTIER B et al.: Effect of baseline genotype on response to tipranavir/ritonavir (TPV/r) compared with standard-of-care comparator (CPI/r) in treatment-experienced patients: the Phase III RESIST-1 and -2 trials. 12th Conference on Retroviruses and Opportunistic Infections, Boston, USA (February 22 - 25 2005) (Abstract 104).
-
(2005)
12th Conference on Retroviruses Opportunistic Infections
-
-
Schapiro, J.M.1
Cahn, P.2
Trottier, B.3
|